Dr Hurvitz concluded that data from BOLERO-1 validates the preliminary observation from BOLERO-3 [4] that treatment effect of everolimus differs based on ER expression in patients with HER-2+ advanced breast cancer in the absence of hormonal therapy. This evidence concerns the gene ESR1 and breast cancer.